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A novel assay for the measurement of activated thrombin activatable fibrinolysis 
inhibitor (TAFIa) activity 
Importance of Project 
 The proper functioning of the circulatory system relies on a balance between the 
coagulation and fibrinolysis cascades. Blood clot formation at a site of vascular injury 
prevents excessive blood loss and allows cellular repair, while subsequent clot dissolution 
ensures that blood circulation is restored. Thrombin activatable fibrinolysis inhibitor 
(TAFI) is a human plasma zymogen that plays an important role in maintaining this 
balance. Activated TAFI (TAFIa), a basic carboxypeptidase enzyme, attenuates the 
fibrinolytic positive feedback cascade by cleaving carboxyl-terminal lysine residues in 
partially-degraded fibrin. TAFI is activated by proteolytic cleavage in response to 
activation of coagulation. Since excessive blood loss, characteristic of hemophilia, as 
well as thrombotic events, as seen in heart attacks and strokes, are related to an imbalance 
in these cascades, the study of TAFI is of great importance to the medical field. The role 
of TAFI in wound healing, inflammation and cancer cell metastasis are additional areas 
of current research.   
Existing State of Knowledge 
 The ability to accurately measure TAFIa activity is pivotal to understanding the 
function and regulation of TAFI in biological systems. Various methods are available for 
the detection of TAFIa, including the immunological method ELISA, enzymological 
assays and functional assays. Enzymological assays exploit the carboxypeptidase activity 
of TAFIa for cleavage of carboxyl-terminal arginine and lysine residues from small 
substrates containing a chromophore. This is advantageous in comparison to ELISA, 
since only TAFIa fragments are measured, not the zymogen nor inactive fragments of 
TAFIa. Two current classes of substrates for the enzymatic study of TAFIa include the 
hippuryl-arginine/lysine and anisylazoformyl-arginine/lysine assays, which possess 
various pitfalls. For instance, turbidity resulting from blood clot formation interferes with 
reading the absorbance of a chromogenic substrate or product in the assay. Additionally, 
low concentrations of TAFIa cannot be detected as the assays are not particularly 
sensitive and the activity of TAFIa cannot be monitored in real time. In comparison, a 
functional TAFIa assay designed by Kim and coworkers is very sensitive, allowing 
measurement of picomolar concentrations of TAFIa in plasma. It also utilizes 
fluorescence detection, which avoids the issue of turbidity interference for absorbance 
measurements. Despite these advantages, the numerous purified protein components that 
must be prepared for this assay may lead to inconsistent results. Moreover, TAFIa 
activity cannot be measured in real time using this assay.  
Research Question 
 Thus, the focus of my project is to design and optimize a novel fluorescence assay 
for the measurement of TAFIa activity in real time, with increased sensitivity compared 
to current methods.  
Methodology 
 Baby hamster kidney (BHK) cells expressing recombinant poly-histidine tagged 
wild type TAFI have been cultured, followed by protein purification, to acquire pure wild 
type TAFI protein. Complete activation of TAFI to TAFIa is achieved with a serine 
protease enzyme, thrombin (IIa), in complex with its cofactor thrombomodulin (TM). 
The synthetic substrate designed for the assay is a peptide composed of four amino acids 
(GAGR) modified with an amino-terminal tetramethylrhodamine (TAMRA) fluorophore. 
An anionic quencher, Evan’s Blue dye, interacts electrostatically with the positively 
charged carboxyl-terminal arginine in the substrate, quenching TAMRA’s fluorescence. 
Arginine cleavage by TAFIa releases the associated quencher resulting in a measurable 
increase in fluorescence, indicative of TAFIa activity.  
Findings 
 Thus far, my research has shown that the cleavage of the TAMRA-GAGR peptide 
by TAFIa is measurable as an increase in fluorescence intensity and thus, in principle, the 
assay is a promising means of measuring TAFIa activity. Optimization of the assay will 
be conducted in terms of the relative concentrations of fluorescent substrate and 
quencher, as will development of a TAFIa standard curve. The sensitivity of the assay 
will be explored further, which is important due to the low TAFIa concentration (20 – 
100 pmol/L) present in human plasma. This assay will be applied to measuring TAFIa 
activity natively present in plasma samples and total TAFI concentrations (after 
activation by IIa-TM) present in plasma, tissue or secreted by cells. It will also be applied 
to routine characterization of TAFI, such as after purification of recombinant variants. 
The ability to study TAFIa generation in real time within clots will allow further insight 
into the regulation of TAFIa elaboration in response to thrombogenic stimuli. There is 
also potential to identify individuals at risk for hematological or vascular diseases based 
on variation in plasma TAFI levels or altered TAFIa generation and function.  
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